bioRxivCancer BiologyPreprint
Using evolutionary constraint to define novel candidate driver genes in medulloblastoma
A. Roy, S. Sakthikumar, S. V. Kozyrev, J. Nordin, R. Pensch, M. E. Pettersson, E. Karlsson, K. Lindblad-Toh, K. Forsberg-Nilsson
Abstract
Current knowledge of cancer genomics is biased against non-coding mutations. Here, we use whole genome sequencing data from pediatric brain tumors, combined with evolutionary constraint inferred from 240 mammals to identify genes enriched in non-coding constraint mutations (NCCMs). We compare medulloblastoma (MB, malignant) to pilocytic astrocytoma (PA, benign) and find drastically different NCCM frequencies between the two. In PA, a high NCCM frequency only affects the BRAF locus, while in MB, >500 genes have high levels of NCCMs. Intriguingly, many genes are associated with different age of onset, such as HOXB1 in young patients and NUAK1 in adult patients. Our analysis points to different molecular pathways in different patient groups. These novel candidate driver genes may assist patient stratification in MB and may be useful for treatment options. One-Sentence SummaryNon-coding constraint mutations implicate novel candidate genes to stratify medulloblastoma by age and subgroups.
- organism: human
- assay: whole-genome sequencing
- research focus: differential expression
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Population-based whole-genome sequencing with constrained gene analysis identifies predisposing germline variants in children with central nervous system tumors
Ulrik Kristoffer Stoltze, Jon Foss-Skiftesvik, … Karin Wadt·medRxiv·Mar 1, 2022
- Medulloblastoma oncogene aberrations are not involved in tumor initiation, but essential for disease progression and therapy resistance
K. Okonechnikov, P. Joshi, … S. M. Pfister·bioRxiv·Feb 9, 2024
- Noncoding regulatory mutations contribute to the aberrant gene expression profile of neuroblastomas.
Brianna Jones, Gaurav Seth, … Arko Sen·bioRxiv·Sep 17, 2026
- CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma
Carlos Custodia, Rita Cascão, … Claudia C Faria·bioRxiv·Oct 13, 2026
- Convergent mutations in tissue-specific regulatory regions reveal novel cancer drivers
N. Sinnott-Armstrong, J. A. Seoane, … M. P. Snyder·bioRxiv·Aug 21, 2020
- The landscape of extrachromosomal circular DNA in medulloblastoma
O. S. Chapman, J. Luebeck, … L. Chavez·bioRxiv·Oct 18, 2021